Silent suppression for Antisense

By Dylan Bushell-Embling
Wednesday, 15 October, 2008

Preclinical trials of Antisense Therapeutics’ [ASX: ANP] ATL1101 candidate have been shown to suppress human prostate tumour growth in animal models.

ATL1101 suppressed the growth of human tumours in mice that had been implanted with human prostate cancer sells.

The treatment slowed down the cancerous cells' transition to the most dangerous form of prostate cancer, castration-resistant prostate cancer [CRPC].

The study was conducted with the assistance of Martin Gleave, the director of the Prostate Centre at Vancouver General Hospital.

This is the first known demonstration of the efficacy of RNA-silencing IGF-I receptor drugs in prostate cancer models.

Content from other channels on our network

SPC Global to close facility in Vic under demand-led strategy

CSIRO and AMRF Connect partner on advanced manufacturing program

Circular connectors: small components playing a big role in Australian industry

Quantum Edge: redefining secure industrial wireless for critical infrastructure

Australian researchers create graphene from peanut waste

ABARES predicts Australia's produce will exceed $100bn in 2026–27

Nutrient content claims on alcohol, Australian research

Fast detection of beverage spoilage using the SureTect Multiplex PCR Assay

HVAC&R behind the scenes of food: the systems, skills and standards shaping the next decade

Machinery Regulation will be Mandatory in Less Than a Year — Are You Ready?

UNSW tracks groundwater recharging: study

$320m to power Western Sydney International Airport

Water-repellent membrane advances desalination

Aussie-made remote telemetry unit tech expands into NZ

High-integrity carbon scale to be discussed at Climate Action Week